Table 2 Clinicopathologic features of the UIHC cohort
From: Primary tumor microbiomes predict distant metastasis of colorectal cancer
UIHC cohort, FFPE biospecimens | 0–5 year MFS | >5 year MFS | Test | p |
|---|---|---|---|---|
Patients, n | 50 | 50 | ||
Age, mean year (CI) | 54 (3) | 58 (5) | t test | 0.1 |
Sex, n | Fisher | 0.3 | ||
Female | 15 | 20 | ||
Male | 35 | 30 | ||
Follow-up, median year (IQR) | 0 (0–0.5) | 5.1 (4.5–5.5) | ||
Pathologic stage, n | ||||
T stage | Chi sq. | 0.3 | ||
1 | 0 | 3 | ||
2 | 4 | 9 | ||
3 | 37 | 30 | ||
4 | 9 | 8 | ||
N stage | Chi sq. | 0.4 | ||
0 | 13 | 13 | ||
1 | 21 | 25 | ||
2 | 16 | 11 | ||
X | 0 | 1 | ||
M stage | Chi sq. | <0.001 | ||
1a | 22 | 0 | ||
1b | 4 | 0 | ||
1c | 2 | 0 | ||
X | 22 | 43 | ||
Grade, n | Chi sq. | 0.1 | ||
Well differentiated | 9 | 18 | ||
Moderately diff. | 32 | 23 | ||
Poorly diff. | 9 | 9 | ||
Lymphovasc. invasion, n | Fisher | 0.8 | ||
Present | 32 | 30 | ||
Absent | 18 | 20 | ||
Microsatellite status, n | <0.001 | |||
MSI | 0 | 11 | ||
MSS | 50 | 39 | ||
Neoadjuvant therapy, n | Fisher | >0.9 | ||
Yes | 36 | 35 | ||
No | 14 | 15 | ||
Adjuvant therapy, n | Fisher | <0.001 | ||
Chemotherapy | 49 | 40 | ||
Radiation therapy | 16 | 4 |
